278 related articles for article (PubMed ID: 16972949)
1. CD99 immunoreactivity in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma: a useful diagnostic marker.
Hartel PH; Jackson J; Ducatman BS; Zhang P
J Cutan Pathol; 2006 Sep; 33 Suppl 2():24-8. PubMed ID: 16972949
[TBL] [Abstract][Full Text] [Related]
2. CD99 immunoreactivity in atypical fibroxanthoma: a common feature of diagnostic value.
Monteagudo C; Calduch L; Navarro S; Joan-Figueroa A; Llombart-Bosch A
Am J Clin Pathol; 2002 Jan; 117(1):126-31. PubMed ID: 11789717
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of low-affinity nerve growth factor receptor (P 75) immunostaining in atypical fibroxanthoma.
Bull C; Mirzabeigi M; Laskin W; Dubina M; Traczyc T; Guitart J; Gerami P
J Cutan Pathol; 2011 Aug; 38(8):631-5. PubMed ID: 21623867
[TBL] [Abstract][Full Text] [Related]
4. Atypical fibroxanthoma and malignant fibrous histiocytoma.
Withers AH; Brougham ND; Barber RM; Tan ST
J Plast Reconstr Aesthet Surg; 2011 Nov; 64(11):e273-8. PubMed ID: 21664889
[TBL] [Abstract][Full Text] [Related]
5. CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma.
Kanner WA; Brill LB; Patterson JW; Wick MR
J Cutan Pathol; 2010 Jul; 37(7):744-50. PubMed ID: 20184665
[TBL] [Abstract][Full Text] [Related]
6. Immunoreactivity of CD99 in invasive malignant melanoma.
Wilkerson AE; Glasgow MA; Hiatt KM
J Cutan Pathol; 2006 Oct; 33(10):663-6. PubMed ID: 17026517
[TBL] [Abstract][Full Text] [Related]
7. Immunoexpression of ultraviolet photoproducts and p53 mutation analysis in atypical fibroxanthoma and superficial malignant fibrous histiocytoma.
Sakamoto A; Oda Y; Itakura E; Oshiro Y; Nikaido O; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2001 Jun; 14(6):581-8. PubMed ID: 11406660
[TBL] [Abstract][Full Text] [Related]
8. Reconsidering the diagnostic and prognostic utility of LN-2 for undifferentiated pleomorphic sarcoma and atypical fibroxanthoma.
Hollmig ST; Rieger KE; Henderson MT; West RB; Sundram UN
Am J Dermatopathol; 2013 Apr; 35(2):176-9. PubMed ID: 23000905
[TBL] [Abstract][Full Text] [Related]
9. Atypical fibroxanthoma versus benign and malignant fibrous histiocytoma. A comparative study of their proliferative activity using MIB-1, DNA flow cytometry, and p53 immunostaining.
Oshiro Y; Fukuda T; Tsuneyoshi M
Cancer; 1995 Mar; 75(5):1128-34. PubMed ID: 7850711
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma.
de Feraudy S; Mar N; McCalmont TH
Am J Surg Pathol; 2008 Aug; 32(8):1111-22. PubMed ID: 18545147
[TBL] [Abstract][Full Text] [Related]
11. Recurrent Atypical Fibroxanthoma Versus Malignant Fibrous Histiocytoma.
Branch LG; Albertini JG; Leshin B
J Craniofac Surg; 2015 Jun; 26(4):e322-3. PubMed ID: 26080249
[TBL] [Abstract][Full Text] [Related]
12. Spindle Cell Atypical Fibroxanthoma: Myofibroblastic Differentiation Represents a Diagnostic Pitfall in This Variant of AFX.
Harding-Jackson N; Sangueza M; Mackinnon A; Suster S; Plaza JA
Am J Dermatopathol; 2015 Jul; 37(7):509-14; quiz 515-6. PubMed ID: 26098709
[TBL] [Abstract][Full Text] [Related]
13. H-, K-, and N-ras gene mutation in atypical fibroxanthoma and malignant fibrous histiocytoma.
Sakamoto A; Oda Y; Itakura E; Oshiro Y; Tamiya S; Honda Y; Ishihara A; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2001 Nov; 32(11):1225-31. PubMed ID: 11727262
[TBL] [Abstract][Full Text] [Related]
14. CD163 is not a sensitive marker for identification of atypical fibroxanthoma.
Beer TW
J Cutan Pathol; 2012 Jan; 39(1):29-32. PubMed ID: 22211334
[TBL] [Abstract][Full Text] [Related]
15. LN2, CD10, and Ezrin Do Not Distinguish Between Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma or Predict Clinical Outcome.
Hanlon A; Stasko T; Christiansen D; Cyrus N; Galan A
Dermatol Surg; 2017 Mar; 43(3):431-436. PubMed ID: 28079637
[TBL] [Abstract][Full Text] [Related]
16. [Atypical fibroxanthoma and pleomorphic dermal sarcoma].
Ziemer M; Jäger IM; Dippel E
Hautarzt; 2019 Sep; 70(9):661-669. PubMed ID: 31468069
[TBL] [Abstract][Full Text] [Related]
17. Procollagen 1 expression in atypical fibroxanthoma and other tumors.
Jensen K; Wilkinson B; Wines N; Kossard S
J Cutan Pathol; 2004 Jan; 31(1):57-61. PubMed ID: 14675286
[TBL] [Abstract][Full Text] [Related]
18. Atypical Fibroxanthoma - Histological Diagnosis, Immunohistochemical Markers and Concepts of Therapy.
Koch M; Freundl AJ; Agaimy A; Kiesewetter F; Künzel J; Cicha I; Alexiou C
Anticancer Res; 2015 Nov; 35(11):5717-35. PubMed ID: 26503993
[TBL] [Abstract][Full Text] [Related]
19. Atypical fibroxanthoma presenting immunoreactivity against CD10 and CD99.
Nakamura Y; Abe Y; Ichimiya M; Muto M
J Dermatol; 2010 Apr; 37(4):387-9. PubMed ID: 20507414
[No Abstract] [Full Text] [Related]
20. Superficial malignant fibrous histiocytoma presenting as recurrent atypical fibroxanthoma.
Ly H; Selva D; James CL; Huilgol SC
Australas J Dermatol; 2004 May; 45(2):106-9. PubMed ID: 15068457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
